Ricardo Millán-González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ricardo Millán-González has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Esteban Zavaleta-Monestel
Hospital Pharmacy Section, International Pharmaceutical Federation, The Hague, ZH, The Netherlands
3 shared publications - Jeaustin Mora-Jiménez
Health Research Department, Clínica Bíblica, San José 1307-1000, Costa Rica
3 shared publications - Luis Guillermo Herrera-Jiménez
Department of Pharmacy, University of Costa Rica, San Jose 11501-2060, Costa Rica
3 shared publications - Sebastián Arguedas-Chacón
Health Research Department, Clínica Bíblica, San José 1307-1000, Costa Rica
3 shared publications José María Gutiérrez
Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica
2 shared publicationsFabián Bonilla-Murillo
Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica
1 shared publication
Latest Publications
- Open Access
- 3 October 2026
- Published by MDPI AG in Psychoactives
- Vol. 5 (4) , 27
Private-Sector Sales Trends of Antidepressants and Antipsychotics in Costa Rica, 2022–2026: An Aggregate Analysis by Active Ingredient
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.
- 3 October 2026
- Published by MDPI AG in Psychoactives
- Vol. 5 (4) , 27
Open AccessPrivate-Sector Sales Trends of Antidepressants and Antipsychotics in Costa Rica, 2022–2026: An Aggregate Analysis by Active Ingredient
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.
- Open Access
- 11 August 2026
- Published by American Psychiatric Association Publishing in Psychiatric Research and Clinical Practice
Artificial Intelligence in Psychiatry: Five Decades of Progress and Persistent Translational Challenges
Objective: This review examined the historical development of artificial intelligence (AI) in psychiatry from 1972 to 2025 and identified persistent barriers to clinical translation. Method: The review used a structured source‐identification approach across PubMed/MEDLINE, Web of Science, Google Scholar, ScienceDirect, citation tracking, and targeted historical searches. It synthesized sources qualitatively and organized them chronologically. A structured evidence table summarized representative milestones by era, AI paradigm, clinical task, data modality, validation approach, implementation status, and translational limitation. Results: Psychiatric AI evolved from symbolic simulation and rule‐based expert systems to connectionist models, supervised machine learning, computational psychiatry, digital phenotyping, multimodal monitoring, digital mental health tools, and large language models. Despite increasing computational sophistication, recurring barriers persisted, including uncertain target validity, diagnostic heterogeneity, limited external validation, poor transportability, interpretability challenges, workflow integration, equity, patient trust, and governance. Across eras, technical progress was cyclical rather than linear, with successive waves reproducing unresolved clinical and implementation challenges. Conclusions: The clinical impact of psychiatric AI will likely depend less on algorithmic novelty alone than on clearer clinical targets, prospective validation, implementation trials, patient‐centered evaluation, equity‐sensitive generalizability, and mental health–specific governance. Relevance to Clinical Practice: For routine psychiatric care, AI tools require evidence of clinical validity, transportability, workflow compatibility, patient acceptability, equity, and appropriate governance rather than technical performance alone.
- 11 August 2026
- Published by American Psychiatric Association Publishing in Psychiatric Research and Clinical Practice
Open AccessArtificial Intelligence in Psychiatry: Five Decades of Progress and Persistent Translational Challenges
Objective: This review examined the historical development of artificial intelligence (AI) in psychiatry from 1972 to 2025 and identified persistent barriers to clinical translation. Method: The review used a structured source‐identification approach across PubMed/MEDLINE, Web of Science, Google Scholar, ScienceDirect, citation tracking, and targeted historical searches. It synthesized sources qualitatively and organized them chronologically. A structured evidence table summarized representative milestones by era, AI paradigm, clinical task, data modality, validation approach, implementation status, and translational limitation. Results: Psychiatric AI evolved from symbolic simulation and rule‐based expert systems to connectionist models, supervised machine learning, computational psychiatry, digital phenotyping, multimodal monitoring, digital mental health tools, and large language models. Despite increasing computational sophistication, recurring barriers persisted, including uncertain target validity, diagnostic heterogeneity, limited external validation, poor transportability, interpretability challenges, workflow integration, equity, patient trust, and governance. Across eras, technical progress was cyclical rather than linear, with successive waves reproducing unresolved clinical and implementation challenges. Conclusions: The clinical impact of psychiatric AI will likely depend less on algorithmic novelty alone than on clearer clinical targets, prospective validation, implementation trials, patient‐centered evaluation, equity‐sensitive generalizability, and mental health–specific governance. Relevance to Clinical Practice: For routine psychiatric care, AI tools require evidence of clinical validity, transportability, workflow compatibility, patient acceptability, equity, and appropriate governance rather than technical performance alone.
- Open Access
- 22 June 2026
- Published by MDPI AG in Psychiatry International
- Vol. 7 (3) , 140
Peripheral Inflammatory Biomarkers in First-Episode, Drug-Naïve Major Depressive Disorder: A Systematic Review
Major depressive disorder (MDD) is clinically heterogeneous, and peripheral inflammatory biomarkers may help clarify early biological mechanisms before illness chronicity or pharmacologic treatment confound interpretation. This systematic review synthesized evidence on peripheral inflammatory biomarkers in first-episode, drug-naïve major depressive disorder (FEDN-MDD) compared with healthy controls and examined associations with clinical severity. Following PRISMA 2020, searches of PubMed/MEDLINE, Embase, PsycINFO, and Scopus from inception to 19 March 2026 identified 313 records; after screening, 16 publications were included in qualitative synthesis. Studies varied in age group, biological matrix, assay platform, and statistical reporting, precluding meta-analysis. The most frequently assessed biomarkers were IL-1β, TNF-α, IL-6, and CRP/hs-CRP. IL-6 showed the clearest recurrent tendency toward elevation in FEDN-MDD, whereas CRP/hs-CRP findings were partially positive but methodologically limited. TNF-α and IL-1β findings were mixed, and clinical correlations with depressive severity were sparse and inconsistent. Overall, the evidence supports heterogeneous early immune dysregulation in a subset of patients with FEDN-MDD rather than a single reproducible inflammatory signature. Peripheral inflammatory biomarkers should currently be considered research tools for biological stratification and mechanistic hypothesis generation, pending larger standardized longitudinal studies.
- 22 June 2026
- Published by MDPI AG in Psychiatry International
- Vol. 7 (3) , 140
Open AccessPeripheral Inflammatory Biomarkers in First-Episode, Drug-Naïve Major Depressive Disorder: A Systematic Review
Major depressive disorder (MDD) is clinically heterogeneous, and peripheral inflammatory biomarkers may help clarify early biological mechanisms before illness chronicity or pharmacologic treatment confound interpretation. This systematic review synthesized evidence on peripheral inflammatory biomarkers in first-episode, drug-naïve major depressive disorder (FEDN-MDD) compared with healthy controls and examined associations with clinical severity. Following PRISMA 2020, searches of PubMed/MEDLINE, Embase, PsycINFO, and Scopus from inception to 19 March 2026 identified 313 records; after screening, 16 publications were included in qualitative synthesis. Studies varied in age group, biological matrix, assay platform, and statistical reporting, precluding meta-analysis. The most frequently assessed biomarkers were IL-1β, TNF-α, IL-6, and CRP/hs-CRP. IL-6 showed the clearest recurrent tendency toward elevation in FEDN-MDD, whereas CRP/hs-CRP findings were partially positive but methodologically limited. TNF-α and IL-1β findings were mixed, and clinical correlations with depressive severity were sparse and inconsistent. Overall, the evidence supports heterogeneous early immune dysregulation in a subset of patients with FEDN-MDD rather than a single reproducible inflammatory signature. Peripheral inflammatory biomarkers should currently be considered research tools for biological stratification and mechanistic hypothesis generation, pending larger standardized longitudinal studies.
- Open Access
- 27 June 2025
- Published by Colegio de Medicos y Cirujanos de Costa Rica in Acta Medica Costarricense
- Vol. 67 (1) , 1-4
Suicidio en profesionales de la salud: retos para toda una sociedad
El suicidio en personal de salud es un problema global que previamente no había sido estudiado en Costa Rica. En el presente número de Acta Médica Costarricense, Mora-Torres y colaboradores abordan su ocurrencia a lo largo de 10 años en una muestra retrospectiva de autopsias realizadas en la Sección de Patología Forense del Organismo de Investigación Judicial. Los factores de riesgo detectados más importantes son el sexo masculino, ser profesional en enfermería o medicina y tener antecedentes psiquiátricos. Algunos de los factores que podrían explicar el suicidio en personal de salud son la cultura médica predominante, el síndrome de burnout, los fenómenos postraumáticos y la disociación, las espirales nocivas crecientes de ambientes de hostilidad y bajo rendimiento académico, así como las circunstancias culturales de algunos de los estudiantes de medicina actuales y del futuro. Acciones concretas ante este escenario podrían ser el ejercicio de mentoría docente desde etapas tempranas, la conciliación entre el número de horas trabajadas y las expectativas y demandas del sistema, la adecuada oferta y normalización de los servicios de atención en salud mental, la temprana detección de fenómenos postraumáticos, la instauración de intervenciones adaptadas por género y la implementación de estrategiasorganizacionales para reducir el estrés crónico y el estigma. Algunos de los recursos existentes a los que se puede acudir son la atención psiquiátrica dentro de la clínica de especialidades médicas del Colegio de Médicos y Cirujanos de Costa Rica y la Red Integral de Promoción del Bienestar y Apoyo de la Salud Mental del Sistema de Estudios de Posgrado de la Universidad de Costa Rica.
- 27 June 2025
- Published by Colegio de Medicos y Cirujanos de Costa Rica in Acta Medica Costarricense
- Vol. 67 (1) , 1-4
Open AccessSuicidio en profesionales de la salud: retos para toda una sociedad
El suicidio en personal de salud es un problema global que previamente no había sido estudiado en Costa Rica. En el presente número de Acta Médica Costarricense, Mora-Torres y colaboradores abordan su ocurrencia a lo largo de 10 años en una muestra retrospectiva de autopsias realizadas en la Sección de Patología Forense del Organismo de Investigación Judicial. Los factores de riesgo detectados más importantes son el sexo masculino, ser profesional en enfermería o medicina y tener antecedentes psiquiátricos. Algunos de los factores que podrían explicar el suicidio en personal de salud son la cultura médica predominante, el síndrome de burnout, los fenómenos postraumáticos y la disociación, las espirales nocivas crecientes de ambientes de hostilidad y bajo rendimiento académico, así como las circunstancias culturales de algunos de los estudiantes de medicina actuales y del futuro. Acciones concretas ante este escenario podrían ser el ejercicio de mentoría docente desde etapas tempranas, la conciliación entre el número de horas trabajadas y las expectativas y demandas del sistema, la adecuada oferta y normalización de los servicios de atención en salud mental, la temprana detección de fenómenos postraumáticos, la instauración de intervenciones adaptadas por género y la implementación de estrategiasorganizacionales para reducir el estrés crónico y el estigma. Algunos de los recursos existentes a los que se puede acudir son la atención psiquiátrica dentro de la clínica de especialidades médicas del Colegio de Médicos y Cirujanos de Costa Rica y la Red Integral de Promoción del Bienestar y Apoyo de la Salud Mental del Sistema de Estudios de Posgrado de la Universidad de Costa Rica.
- Open Access
- 31 December 2024
- Published by Colegio de Medicos y Cirujanos de Costa Rica in Acta Medica Costarricense
- Vol. 66 (2) , 1-6
Formulación biológica: ¿necesitamos un nuevo paradigma de razonamiento clínico en psiquiatría?
Aim: to redefine the prevalent clinical reasoning model applied to patients with psychiatric illness and to identify semiological strategies that can stablish a guide towards integrative care. Methos: directed bibliographic review and presentation of the concept of biological formulation in the clinical practice of integrative psychiatry. Results: the need to redefine the clinical reasoning model is justified, the establishment of a semiological guide - biological formulation - is defined and key questions for the detection of physiological imbalances or the integration of physical illness into the understanding of psychiatric pathology are identified. Some of these questions are: (1) what is the cause or causes of the physiological imbalance/allostatic overload/inflammatory response in this patient? (2) What is the common root that this patient's physical illness shares with the psychiatric symptomatology? (3) Instead of “excluding medical causes” of psychiatric illness, what is the role and how can physical illness or physiological imbalances be integrated into the understanding of the psychiatric syndrome? (4) What are the vicious cycles that perpetuate the interaction between physiological imbalance/allostatic overload/inflammatory response/physical illness and psychiatric pathology? (5) How and with what mechanisms does the physical condition interfere with the psychiatric symptoms? (6) How do we proceed to correct these alterations, so that the body - and, consequently, the brain - has a greater adaptive capacity in the face of different stressors? Conclusion: in psychiatry, traditional models are insufficient in many cases. Integrative approaches, guided by a biological formulation, that consider the understanding of the interaction between the physiological reserve, the physical conditions and the psychiatric pathology, are capable of detecting pathophysiological mechanisms that, if not considered, could be associated with inadequate responses to the clinical interventions, and, therefore, to non-pharmacological resistance to treatment.
- 31 December 2024
- Published by Colegio de Medicos y Cirujanos de Costa Rica in Acta Medica Costarricense
- Vol. 66 (2) , 1-6
Open AccessFormulación biológica: ¿necesitamos un nuevo paradigma de razonamiento clínico en psiquiatría?
Aim: to redefine the prevalent clinical reasoning model applied to patients with psychiatric illness and to identify semiological strategies that can stablish a guide towards integrative care. Methos: directed bibliographic review and presentation of the concept of biological formulation in the clinical practice of integrative psychiatry. Results: the need to redefine the clinical reasoning model is justified, the establishment of a semiological guide - biological formulation - is defined and key questions for the detection of physiological imbalances or the integration of physical illness into the understanding of psychiatric pathology are identified. Some of these questions are: (1) what is the cause or causes of the physiological imbalance/allostatic overload/inflammatory response in this patient? (2) What is the common root that this patient's physical illness shares with the psychiatric symptomatology? (3) Instead of “excluding medical causes” of psychiatric illness, what is the role and how can physical illness or physiological imbalances be integrated into the understanding of the psychiatric syndrome? (4) What are the vicious cycles that perpetuate the interaction between physiological imbalance/allostatic overload/inflammatory response/physical illness and psychiatric pathology? (5) How and with what mechanisms does the physical condition interfere with the psychiatric symptoms? (6) How do we proceed to correct these alterations, so that the body - and, consequently, the brain - has a greater adaptive capacity in the face of different stressors? Conclusion: in psychiatry, traditional models are insufficient in many cases. Integrative approaches, guided by a biological formulation, that consider the understanding of the interaction between the physiological reserve, the physical conditions and the psychiatric pathology, are capable of detecting pathophysiological mechanisms that, if not considered, could be associated with inadequate responses to the clinical interventions, and, therefore, to non-pharmacological resistance to treatment.
- Open Access
- 20 April 2024
- Published by Colegio de Medicos y Cirujanos de Costa Rica in Acta Medica Costarricense
- Vol. 66 (1) , 1-5
Prevención de suicidio: entendiendo la enfermedad como proceso
El suicidio es un problema de salud pública. La prevención requiere de acciones formativas a nivel emocional, del tratamiento científico de las situaciones de riesgo suicida y de un manejo sensible por parte de los medios de comunicación. A raíz de las efemérides del día mundial de la prevención del suicidio y del día mundial de la salud mental, conviene hacer una reflexión sobre cómo la conceptualización de la enfermedad como proceso facilita el abordaje de los trastornos mentales. La comprensión de la historia de vida de cada paciente permite realizar una adecuada contextualización biográfica que explica la compleja interacción entre estrés temprano en la vida, vulnerabilidad, epigenética y circunstancias vitales, sociales y ambientales. Congruente con este trabajo clínico, la labor médica debe centrarse también en la participación en programas de educación médica continua y desde la escuela de medicina y en el diseño de acciones de promoción/prevención que consideren esta visión del continuum salud-enfermedad y que entiendan la salud física y mental como unidad. Lo anterior se fortalece con el desarrollo de las propias capacidades introspectivas para la detección del desgaste profesional como mecanismo de pérdida de la empatía.
- 20 April 2024
- Published by Colegio de Medicos y Cirujanos de Costa Rica in Acta Medica Costarricense
- Vol. 66 (1) , 1-5
Open AccessPrevención de suicidio: entendiendo la enfermedad como proceso
El suicidio es un problema de salud pública. La prevención requiere de acciones formativas a nivel emocional, del tratamiento científico de las situaciones de riesgo suicida y de un manejo sensible por parte de los medios de comunicación. A raíz de las efemérides del día mundial de la prevención del suicidio y del día mundial de la salud mental, conviene hacer una reflexión sobre cómo la conceptualización de la enfermedad como proceso facilita el abordaje de los trastornos mentales. La comprensión de la historia de vida de cada paciente permite realizar una adecuada contextualización biográfica que explica la compleja interacción entre estrés temprano en la vida, vulnerabilidad, epigenética y circunstancias vitales, sociales y ambientales. Congruente con este trabajo clínico, la labor médica debe centrarse también en la participación en programas de educación médica continua y desde la escuela de medicina y en el diseño de acciones de promoción/prevención que consideren esta visión del continuum salud-enfermedad y que entiendan la salud física y mental como unidad. Lo anterior se fortalece con el desarrollo de las propias capacidades introspectivas para la detección del desgaste profesional como mecanismo de pérdida de la empatía.
- 1 March 2012
- Published by Elsevier in Revista Colombiana de Psiquiatría
- Vol. 41 (1) , 150-164
Consentimientos informados y aprobación por parte de los comités de ética en los estudios de antipsicóticos atípicos para el manejo del delírium
- 1 March 2012
- Published by Elsevier in Revista Colombiana de Psiquiatría
- Vol. 41 (1) , 150-164
Consentimientos informados y aprobación por parte de los comités de ética en los estudios de antipsicóticos atípicos para el manejo del delírium